Editorial—BioPharm Reflects the Industry

Welcome to the inaugural issue of the new BioPharm International. We are pleased to unveil our new logo and redesign after collaborating for four months with award-winning designer Virginia Dickens of Vision Advertising. One of our redesign goals was for the magazine to reflect the same innovative, cutting-edge qualities that are characteristic of the evolving biopharm industry. Probably more important to you is how the new format will better accommodate the expression of your day-to-day challenges.

Carol L. Fisher

We understand you must juggle the development of new technologies while streamlining operations. You create strategic alliances that require your adjustment to new business paradigms. You build cGMP-compliant plants and strive to meet FDA guidelines and requirements. You implement new business models to ensure rewarding career paths for your employees and long-term value for the shareholders. Then there's the science — the foundation of your professional existence and the primary focus of BioPharm International.

We've added new elements to make BioPharm the first "must-read" publication on your desk. Global News Network offers developments most likely to affect your professional efforts. You'll know how regions, states, and countries are preparing to become the next biotech hubs by reading Regional Round-Up and International BioMarket

Besides upgrading the magazine, we've made changes to our website (www.biopharm-mag.com), including a user-friendly home page that now hosts daily news.

The staff has evolved too. With the addition of Ivette Litt as art director, the transition of BioPharm headquarters from Eugene, OR to Iselin, NJ is complete. Ivette bravely accepted the task of introducing the redesign while also preparing the 21 CFR Part 11 supplement.

Michael McGregor recently joined the team as senior editor in charge of news, supplements, and primers. Previously, Michael worked with the Manisses Communications Group, Princeton Review, and Brown University. Peter Silverberg, associate editor, trained at MIT in chemical engineering and has extensive editorial experience plus a broad base of practical knowledge as a chemical and analytical engineer.

BioPharm appreciates your challenges, and we intend to support you with the most sophisticated tools, processes, and staff in the business.

Carol L. Fisher, Editor in Chief

BioPharm International

cfisher@advanstar.com